# A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer

> **NCT03380871** · PHASE1 · COMPLETED · sponsor: **BioNTech US Inc.** · enrollment: 38 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Lung Cancer
- Nonsquamous Nonsmall Cell Neoplasm of Lung

## Interventions

- **BIOLOGICAL:** NEO-PV-01
- **BIOLOGICAL:** Pembrolizumab
- **OTHER:** Adjuvant
- **DRUG:** Carboplatin
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT03380871
- **Lead sponsor:** BioNTech US Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-04
- **Primary completion:** 2019-10-31
- **Final completion:** 2021-02-05
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2021-02-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03380871

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03380871, "A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03380871. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*